Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vieworks CoXKRX:100120 -2.37%93 ROE % is 26.03% as of Jun. 2026, which is 77% above its 10-year median of 14.68. GuruFocus rates XKRX:100120 with a GF Score™ of 93/100 and a GF Value™ of ₩28,030.42 (Fairly Valued). The stock has 5 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Vieworks Co ranks better than 88.96% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vieworks Co's annualized net income for the quarter that ended in Jun. 2026 was ₩65,616 Mil. Vieworks Co's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was ₩252,059 Mil. Therefore, Vieworks Co's annualized ROE % for the quarter that ended in Jun. 2026 was 26.03%.
The historical rank and industry rank for Vieworks Co's ROE % or its related term are showing as below:
XKRX:100120'
s ROE % Range Over the Past 10 Years
Min: 6.93 Med: 14.68 Max: 27.68
Current: 17.78
During the past 13 years, Vieworks Co's highest ROE % was 27.68%. The lowest was 6.93%. And the median was 14.68%.
XKRX:100120's ROE % is ranked better than 88.96% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.68
vs XKRX:100120: 17.78
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Vieworks Co ROE % Related Terms
Vieworks Co ROE % Historical Data
* Premium members only.
The historical data trend for Vieworks Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vieworks Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vieworks Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vieworks Co's ROE % distribution charts can be found below:
* The bar in red indicates where Vieworks Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Vieworks Co (XKRX:100120) has a ROE % of 26.03% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vieworks Co and its competitors. This is 77% above median its historical median of 14.68. Over the past decade, Vieworks Co's ROE % has ranged from 6.93 to 27.68. According to the industry distribution chart, Vieworks Co ranks #88 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 11%.
Is Vieworks Co's ROE % too high?
Vieworks Co's current ROE % of 26.03% is 77% above median its 10-year median of 14.68. Over the past 10 years, this metric has ranged from a low of 6.93 to a high of 27.68. The Medical Devices & Instruments industry median ROE % is 2.68. Vieworks Co's value of 26.03% is 871.3% above this industry median. Based on the distribution chart, Vieworks Co ranks #88 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vieworks Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vieworks Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vieworks Co ranks #88 out of 797 companies for ROE %. This places Vieworks Co in the top 11% of its industry — outperforming the majority of peers. The industry median ROE % is 2.68. Vieworks Co's value of 26.03% is 871.3% above this benchmark. Historically, Vieworks Co's own ROE % has ranged from 6.93 to 27.68 over the past decade. While the company's 10-year median is 14.68 vs. the industry median of 2.68, Vieworks Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.68, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vieworks Co's current ROE % of 26.03% is 871.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Vieworks Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vieworks Co's current ROE % is 26.03%, which is 77% above median its own 10-year median of 14.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vieworks Co stock overvalued right now?
Based on GuruFocus' analysis, Vieworks Co (XKRX:100120) is currently considered Fairly Valued. The stock's GF Value™ is ₩28,030.42, compared to a current price of ₩26,750.00 — trading 4.6% below its estimated fair value. The current ROE % is 26.03%, which is 77% above median its 10-year median of 14.68 and 871.3% above the Medical Devices & Instruments industry median of 2.68. Vieworks Co's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Vieworks Co (XKRX:100120), the current ROE % is 26.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vieworks Co (XKRX:100120) Overvalued in 2026?
Based on GuruFocus' analysis, Vieworks Co stock appears to be undervalued.
The current stock price of ₩26,750.00 is trading 4.6% below its estimated GF Value™ of ₩28,030.42.
GuruFocus considers Vieworks Co to be Fairly Valued.
Key valuation signals for XKRX:100120:
ROE %: 26.03% (77% above median its 10-year median of 14.68)
GF Value™: ₩28,030.42 vs. price of ₩26,750.00 (4.6% below fair value)
Industry Position: 871.3% above the Medical Devices & Instruments median (#88 of 797)
No single metric tells the full story. See the XKRX:100120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vieworks Co Ltd designs, develops, manufactures and provides camera systems and digital imaging systems for digital radiography, digital fluoroscopy and angiography systems and also medical imaging processing, signal processing for an image sensor, high precision optics and optomechanical design. Its products include Vivix-S series and D series, Slimpac 2 series, Camera, Lenses etc.
93GF Score
Get the complete analysis for XKRX:100120
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:100120 has been successfully added to your 
